Vyne Therapeutics’ attempt to develop a safer, more tolerable BET inhibitor has hit turbulence. | Vyne Therapeutics’ attempt ...

The CEO and board chair of Belgian biotech Galapagos has announced plans to leave the islands. Paul Stoffels, M.D., will ...

The pipeline purge comes less than a year after Caribou cut 12% of staff and ended its natural killer (NK) cell therapy ...

Over the next four months, the Vaccine Integrity Project will hold information-gathering sessions with medical associations, ...

Mosaic Therapeutics has secured the latest pieces in its combination medicine strategy by licensing two clinical stage tumor ...

A study of almost 34,000 people in rural China has revealed that lowering blood pressure can reduce the risk of dementia in ...

Boston Scientific said that while tariffs pose “unfortunate” headwinds—which are poised to add about $200 million to the cost ...

Big Pharma's M&A plans will likely take a hit if the U.S. government under the Trump administration lives up to its threats ...

Bioengineering nonprofit Cultivarium is embarking on a three-year journey to develop tools and resources for scientists ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Hans Warrinnier, chief medical officer at Bioxodes, said in a statement that the results are preliminary but all point in the ...